

economic evaluation for health

Benefits and Costs of the NCD Targets for the Post-2015 Development Agenda

MOTIVATION

Current Situation

NCDs are a major contributor to mortality and morbidity in low- and middle-income countries (LMICs).

- NCDs account for 65% of global deaths and for a majority of deaths in all regions except sub-Saharan Africa (1)
- NCD mortality exceeds that of communicable, maternal, perinatal and nutritional conditions combined (2)
- 80% of global NCD deaths occur in LMICs, making NCDs a major cause of poverty and an urgent development issue
- \$47 trillion in economic output will likely be lost to NCDs by 2030 (3).

Post-2015 Development Agenda

Goal 3 of the proposed Sustainable Development Goals (SDGs) is: Ensure healthy lives and promote well-being for all at all ages.

Proposed target (3.4) in the Post-2015 SDG Framework aims to: by 2030, reduce premature mortality from NCDs by one-third through prevention and treatment and promote mental health and well-being.

OUR GOAL

We consider five (of many potential) interventions that need to be in place to meet proposed target 3.4, and calculate the cost-benefit ratios of implementing each. These cost-benefit ratios can then be compared across development topics. We find that cost-effective prevention and treatment solutions for NCDs compare favorably to other development goals, and are ready to be scaled-up across the globe.

INTERVENTIONS

We considered five interventions that would need to be in place by 2030 to come close to reaching the NCD target. All five interventions are part of the World Health Assembly's NCD targets.

TOBACCO TAX – Tax tobacco at sufficiently high rates to achieve a 50% relative reduction in user prevalence. In this target, we concentrate on low- and middle-income countries because many high-income countries (HICs) have already implemented significant tax increases.

ASPIRIN THERAPY FOR AMI - Provide aspirin to 75% of patients at the onset of an acute myocardial infarction (AMI).

SALT REDUCTION – 30% reduction in the mean dietary intake of salt through voluntary reformulation of processed foods.

HYPERTENSION MANAGEMENT – Use of hypertension medicine by 50% of those at medium to high risk.

SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE-70% coverage and at least 60% adherence to a multi-pill regimen for those at a high risk of a cardiovascular event.

By Elizabeth Brouwer, MPH, and Rachel Nugent, PhD Disease Control Priorities Network, Department of Global Health, University of Washington

METHODS

To assess the benefits and costs of achieving the proposed post-2015 NCD target, we first calculated the number of deaths to be averted in 2030. Generally speaking, premature deaths are defined as deaths that occur before average life expectancy is reached (about 70 years of age). Our target is a range of projections from two sources; for one source, we took the midpoint of projections from two age groups.				Summary of Intervention Benefits, Costs and Benefit-Cost			
				Target	Annual benefits (\$m)	Annual costs (\$m)	
				Aspirin therapy at the onset of AMI (75% coverage)	\$836	\$27.40	
Source	Age range	Projected NCD deaths in 2030 (in millions)	Deaths to avert to reach target (in millions)	Chronic hypertension management for medium to high-risk patients (50% coverage)	\$11,410	\$500	
WHO Global Health Estimates 2013 (4)	30-69	17.60	5.87	Reduce salt content in manufactured foods by at least 30%	\$12,121	\$638	
Norheim et al 2014 (5)	0-69	23.02	7.67	Increase tobacco price by 125% through taxation	\$37,194	\$3,548	
Norheim et al 2014 (5)	50-69	17.57	5.86	Secondary prevention of CVD with polydrug (70% coverage)	\$13,116	\$3 <i>,</i> 850	
Calculated Target	30-69		5.87 – 6.77 *	Total	\$74,677	\$8,563	
*6.77 is the midpoint between 5.86 and 7.67				Premature deaths averted in 2030 from chosen interventions (5 million deaths averted total)	Costs to in the y	ear 2030 (\$8.5 billion total	
S m deaths of 70 2.5 m avertable, premature deaths s to acco taxes enough globally so that 50% of people under 70 will either quit smoking or never initiate the habit and reach average life expectancy.				 Population sate and population state in value as disease and population transition occur. Tobacco taxation has the farthest reach averting the same restards the same restard of the			
The real price of tobacco would have to increase by 125% for a 50% consumption decrease. This is based upon a generally agreed upon tobacco prevalence elasticity of -0.4. We attach a monetary value to deaths averted by estimating how many extra years of productive life each person would have lived. In this analysis, we averaged each death averted as 15 disability-adjusted life-years gained. Each of those life-years is then valued at \$1,000, which is the average GDP per capita in LMICs, or the average productivity of an active adult. Asaria et al. (6) estimate the average annual cost per capita to implement a revised tobacco tax system is about \$0.50. We multiplied this number by the projected 2030 population to find the total cost of tobacco taxation.				 Aspirin therapy at the onset of AMI provides the highest BCR of analyzed interventions, but has a limited reach to avert deaths Other health system strengthening efforts are necessary to croplatforms for NCD management, our ratios are meant to complement health system strengthening efforts. Citations: Murray CJ, Lopez AD. Measuring the global burden of disease. New England Journal of Medicine 2013; 369(5): Commission OM. Now for the long term, the report of the Oxford Martin Commission for Future Generations. Oxford 2013. Bloom D, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom L, Fathima S. The global economic burden of non communicable diseases. 2011. World Economic Forum, Geneva; 2012 Global Health Stimates Summary Tables: Projection of Deathsy by Cuase, Age, and Sex. July 2013 ed. Geneva, World Health Organization; 2013. Norheim OF, Jha P, Admasu K, et al. Avoiding 40% of the premature deaths in each country, 2010–30: review of mortality trends to help quantify the UN Sustainable Development Goal for health. The Lancet 2014; 385(9964) Asaria, Perviz, et al. "Chronic disease prevention: health effects and financial costs of strategies to reduce salt control disease in the 2720 9604 (2021): 2014 2052. 			



Our denent-cost analysis does not incorporate tax revenue



RESULTS

